NCT02588651

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: COMPLETED

Phase: PHASE2

Sponsor: Deepa Jagadeesh

Condition: T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepato-splenic T-cell Lymphoma, Adult T-cell Leukemia/Lymphoma, Enteropathy Associated T-cell Lymphoma, NK T-cell Lymphoma

Signal summary

Public flags

Status signal: Low Signal

Timeline signals: None

Results signal: Low Signal

Operational burden: strict_eligibility_signal

Stopped reason

Context when available

No stop reason available in the current public record.